Kathryn C. Zoon is Director at Emergent BioSolutions Inc. (EBS). They have made 19 open-market trades across 1 company since 2017, most recently 2026-05-01.
CIK 0001685720
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 19 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| EBS | 79,941 | $510K |
Shares reported on the most recent Form 4, priced at the 2026-05-04 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EBS | SELL · 10b5-1 | 2026-05-01 | 2026-05-04 | $8.40 | $144K | -7.8% | -10.8% | -16.7% |
| EBS | SELL · 10b5-1 | 2025-08-15 | 2025-08-18 | $8.87 | $126K | -7.3% | -13.9% | +11.6% |
| EBS | SELL | 2025-03-12 | 2025-03-12 | $5.73 | $115K | -6.2% | -28.2% | +10.5% |
| EBS | SELL | 2024-06-04 | 2024-06-06 | $6.11 | $61K | -0.7% | +33.3% | +21.1% |
| EBS | SELL | 2024-05-29 | 2024-05-31 | $4.61 | $8K | +12.1% | +25.2% | +58.0% |
| EBS | SELL | 2024-05-21 | 2024-05-23 | $5.78 | $6K | +33.9% | +35.9% | +110.6% |
| EBS | SELL · 10b5-1 | 2023-05-25 | 2023-07-24 | $8.36 | $30K | -0.7% | -37.5% | -70.6% |
| EBS | SELL | 2022-06-09 | 2022-06-13 | $31.52 | $37K | +16.7% | +12.2% | -10.8% |
| EBS | SELL | 2022-05-24 | 2022-05-25 | $35.53 | $142K | -3.1% | -1.9% | -18.3% |
| EBS | SELL | 2021-05-25 | 2021-05-27 | $56.48 | $355K | +7.2% | +3.3% | +6.0% |
| EBS | SELL | 2020-08-10 | 2020-08-11 | $130.27 | $261K | +4.5% | -19.2% | -26.8% |
| EBS | SELL | 2020-05-26 | 2020-05-27 | $85.10 | $697K | -18.4% | -10.5% | +46.9% |
| EBS | SELL | 2020-05-12 | 2020-05-14 | $85.21 | $283K | +4.1% | -12.1% | +60.3% |
| EBS | SELL | 2020-03-04 | 2020-03-06 | $60.65 | $120K | +0.9% | +11.3% | +53.9% |
| EBS | SELL | 2019-11-18 | 2019-11-19 | $54.31 | $54K | -0.3% | +0.3% | +18.7% |
| EBS | SELL | 2019-11-08 | 2019-11-12 | $54.15 | $334K | -6.4% | -1.3% | +12.9% |
| EBS | SELL | 2019-09-09 | 2019-09-10 | $56.12 | $169K | -10.4% | -7.9% | -5.3% |
| EBS | SELL | 2019-05-28 | 2019-05-28 | $43.39 | $119K | +10.2% | +13.8% | -3.2% |
| EBS | SELL | 2018-11-07 | 2018-11-08 | $69.74 | $592K | +3.2% | -0.8% | -5.1% |
| EBS | SELL | 2018-06-06 | 2018-06-07 | $52.81 | $20K | +1.7% | +1.2% | +12.9% |
| EBS | SELL | 2018-05-24 | 2018-05-29 | $51.15 | $141K | +5.3% | -0.2% | +20.2% |
| EBS | SELL | 2017-11-08 | 2017-11-13 | $39.08 | $200K | +2.8% | +13.6% | +16.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.